Results 1 to 10 of about 1,995 (245)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults [PDF]

Npj Vaccines, 2023
Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines.
Nicolas Folschweiller, Edson Duarte Moreira, Mayuri Sharma   +2 more
exaly   +5 more sources

Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis [PDF]

Vaccines
The TAK-003 dengue vaccine was licensed in Europe in December 2022, and the official recommendations from most EU countries are still under formulation. To support policymakers, we performed a meta-analysis to quantify TAK-003’s immunogenicity, efficacy ...
Maria Elena Flacco, Alessandro Bianconi, Giovanni Cioni   +2 more
exaly   +6 more sources

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). [PDF]

PLoS Neglected Tropical Diseases, 2021
The four dengue virus serotypes (DENV1-4) infect several hundred million people each year living in tropical and sub-tropical regions. Clinical development of DENV vaccines is difficult because immunity to a single serotype increases risk of severe ...
Laura J White, Ellen F Young, Mark J Stoops, Sandra R Henein, Elizabeth C Adams, Ralph S Baric, Aravinda M de Silva   +6 more
doaj   +7 more sources

A Methodological Approach to Measuring the Impact of TAK-003 for the Prevention of Dengue in Dourados, Brazil: Optimizing Strategies for Public Health [PDF]

Vaccines
Background/Objectives: Takeda’s tetravalent dengue vaccine TAK-003 has been approved by the Brazilian regulatory agency ANVISA for dengue disease prevention in individuals aged 4 to 60 years. Dourados, in the state of Mato Grosso do Sul, became the world’
Roberto Oliveira, Alberta Di Pasquale, Julio Croda   +2 more
exaly   +6 more sources

Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand. [PDF]

PLoS Medicine
BackgroundDengue is an increasing global problem associated with negative health and economic impacts. Vaccination is an important measure to reduce the significant public health and economic burden caused by dengue.
Jing Shen, Elizaveta Kharitonova, Anna Tytula, Justyna Zawieja, Samuel Aballea, Shibadas Biswal, Mayuri Sharma, Supattra Rungmaitree, Rosarin Sruamsiri, Derek Wallace, Riona Hanley   +10 more
doaj   +5 more sources

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. [PDF]

PLoS Neglected Tropical Diseases, 2023
BackgroundYellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-naïve individuals ...
Vianney Tricou, Brandon Essink, John E Ervin, Mark Turner, Ian Escudero, Martina Rauscher, Manja Brose, Inge Lefevre, Astrid Borkowski, Derek Wallace   +9 more
doaj   +2 more sources

Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database [PDF]

Frontiers in Pharmacology
IntroductionDengue is one of the major global public health burden, particularly in endemic regions. CYD-TDV and TAK-003 are the currently licensed live attenuated tetravalent dengue vaccines, differing in serostatus indication, age range, and ...
Viviana Maria Gianguzzo, Michelangelo Rottura, Federica Maria Sacco, Matthew Gavino Donadu, Giuseppina Sanna, Natasha Irrera, Egidio Imbalzano, Vincenzo Arcoraci, Giuseppinella Melita, Ylenia Marino, Sara Manti, Giovanni Pallio   +11 more
doaj   +2 more sources

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life [PDF]

Human Vaccines & Immunotherapeutics, 2023
Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year.
Sanjay S. Patel, Peter Winkle, Alice Faccin, Francesco Nordio, Inge LeFevre, Claudia Galindo Tsoukas   +5 more
doaj   +2 more sources

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children [PDF]

npj Vaccines
As robust cellular responses are important for protection against dengue, this phase 2 study evaluated the kinetics and phenotype of T cell responses induced by TAK-003, a live-attenuated tetravalent dengue vaccine, in 4–16-year-old living in dengue ...
Sanja Mandaric, Heather Friberg, Xavier Saez-Llorens, Charissa Borja-Tabora, Shibadas Biswal, Ian Escudero, Alice Faccin, Raphael Gottardo, Manja Brose, Nicholas Roubinis, Darlene Fladager, Rodrigo DeAntonio, Julie Anne L. Dimero, Nathali Montenegro, Nicolas Folschweiller, Jeffrey R. Currier, Mayuri Sharma, Vianney Tricou   +17 more
doaj   +2 more sources

The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study [PDF]

Vaccines, 2020
There is a growing public health need for effective preventive interventions against dengue, and a safe, effective and affordable dengue vaccine against the four serotypes would be a significant achievement for disease prevention and control.
Maíra Aguiar, Nico Stollenwerk
doaj   +3 more sources